Table 2.
Characteristics of live‐born singletons from prospectively reported pregnancies with maternal exposure to CZPa
| Characteristic | All (n = 442)b | Rheumatic diseases (n = 252)c | CD (n = 164)c |
|---|---|---|---|
| Cesarean section | 139 (31.4) | 61 (24.2) | 70 (42.7) |
| Gestational age at birth | |||
| Number with available data | 326 | 195 | 120 |
| 20 to <32 weeks | 4 (1.2) | 1 (0.5) | 2 (1.7) |
| 32 to <37 weeks | 35 (10.7) | 22 (11.3) | 12 (10.0) |
| ≥37 weeks | 287 (88.0) | 172 (88.2) | 106 (88.3) |
| Median (range) weeks | 39 (27–43) | 39 (27–43) | 39 (31–42) |
| Birth weight | |||
| Number with available data | 205 | 145 | 55 |
| Low birth weightd | 24 (11.7) | 17 (11.7) | 7 (12.7) |
a
Except where indicated otherwise, values are the number (%). Of 442 singleton infants, 4 (0.9%) were small for gestational age (2 [0.8%] of 252 born to mothers with rheumatic diseases and 2 [1.2%] of 164 born to mothers with Crohn's disease [CD]). CZP = certolizumab pegol.
b
Includes patients with multiple and unknown indications.
c
Includes patients who had both rheumatic diseases and CD.
d
≤2,500 gm.